GHRP-2
Also called Pralmorelin, Growth hormone-releasing peptide-2, GHRP Kaken 100.
GHRP-2 has no FDA-approved product. This page cites 1 source, and the strongest evidence comes from human trials.
- Status
- No FDA-approved product
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 1
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
In a randomized placebo-controlled study of 19 healthy, weight-stable adults, including nine with obesity, subcutaneous GHRP-2 infusion increased growth hormone release and food intake during short laboratory visits.
Limits: The experiment lasted 270 minutes per visit and measured hormones, appetite, and a buffet meal. It did not measure sustained muscle gain, improved physical function, or longevity. Japan's diagnostic product uses intravenous administration.
Regulatory status
United States
GHRP-2 has no FDA-approved human drug product. FDA has identified products containing it as unapproved drugs. Its use in human experiments does not establish approval for growth, muscle gain, or longevity. A Japanese diagnostic authorization applies to a specific pralmorelin product and jurisdiction.
Japan
Japan authorizes pralmorelin hydrochloride as GHRP Kaken 100 for diagnosis of growth hormone deficiency. The product label describes intravenous administration for a monitored stimulation test. This diagnostic use does not authorize ongoing treatment for muscle growth, weight management, or aging.